WO2024147112 - GLYCOENGINEERED POLYPEPTIDES TARGETING IMMUNOGLOBULIN A AND COMPLEXES COMPRISING THE SAME
National phase entry:
Publication Number
WO/2024/147112
Publication Date
11.07.2024
International Application No.
PCT/IB2024/050113
International Filing Date
05.01.2024
Title **
[English]
GLYCOENGINEERED POLYPEPTIDES TARGETING IMMUNOGLOBULIN A AND COMPLEXES COMPRISING THE SAME
[French]
POLYPEPTIDES GLYCOMODIFIÉS CIBLANT L'IMMUNOGLOBULINE A ET COMPLEXES LES COMPRENANT
Applicants **
GLYCOERA AG
Inventors
KAUNDINYA, Ganesh
GANGULY, Tanmoy
FOLLADOR, Rainer
MALLY, Manuela
BACK, Jonathan Albert
MANNI, Michela
Priority Data
63/478,578
05.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4864 | |
| EPO | Filing, Examination, Granting | 69883 | |
| Japan | Filing, Examination, Granting | 4309 | |
| South Korea | Filing, Examination, Granting | 6361 | |
| USA | Filing, Examination, Granting | 20840 |
Total:
106,257
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to a target antibody (e.g., an IgA1 or an immune complex comprising the same, a gd-IgA1 or an immune complex comprising the same, or an anti-gd-IgA1 autoantibody or an immune complex comprising the same) and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and/or nucleic acids encoding the same, as well as methods of making and using the same.[French]
L'invention concerne des polypeptides glycomodifiés comprenant un premier fragment comprenant un ou plusieurs peptides qui se lient de manière spécifique à un anticorps cible (par exemple, un IgA1 ou un complexe immun le comprenant, un gd-IgA1 ou un complexe immun le comprenant, ou un auto-anticorps anti-gd-IgA1 ou un complexe immun le comprenant) et un second fragment comprenant un ou plusieurs glycanes conjugués au premier fragment au niveau d'un ou de plusieurs sites de glycosylation. L'invention concerne également une séquence d'acide nucléique codant pour des polypeptides glycomodifiés selon l'invention. L'invention concerne en outre des compositions comprenant des polypeptides glycomodifiés et/ou des acides nucléiques codant pour ceux-ci, ainsi que leurs procédés de fabrication et d'utilisation.